Institute for Neurodegenerative Disorders
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Institute for Neurodegenerative Disorders sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Institute for Neurodegenerative Disorders: 37 sponsored US clinical trials, none currently recruiting.
Institute for Neurodegenerative Disorders sponsors 37 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 26 completed. 1 of these trials are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson Disease, with 4 trials.
Top-decile sponsor footprint
Institute for Neurodegenerative Disorders ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
26 of 37 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
37 total, page 1 of 1
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
NCT01767493
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
NCT01461083
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
NCT01461109
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
NCT01462708
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
NCT01268020
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513
NCT01000870
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970333
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
NCT00970229
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
NCT00870974
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease
NCT00886951
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00870519
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
NCT00968097
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
NCT00657813
Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
NCT00612872
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00556660
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00605059
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
NCT00605046
Development of Cognitive Assessment Tools in Parkinson Disease
NCT00556764
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
NCT00470925
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
NCT00456417
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
NCT00480701
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
NCT00427674
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
NCT00404170
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
NCT00397696
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants
NCT00354003
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
NCT00316797
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
NCT00287248
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
NCT00273351
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
NCT00315250
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
NCT00096876
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
NCT00096720
A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease
NCT00117195
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
NCT00129675
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease
NCT00117819
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
How the Institute for Neurodegenerative Disorders early-phase archive is shaped
37 indexed studies, none listed as recruiting (0% open); 26 completed (70%).
Phase mix: 1 late (III/IV) vs 33 early (I/II) (early-phase heavy).
Top condition: Parkinson Disease (4 trials), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Institute for Neurodegenerative Disorders: archived-pipeline peers nationwide
Peers matched on 37 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Institute for Neurodegenerative Disorders sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 archived trials
- Appalachian State University · 37 trials · 3% recruiting
- Bracco Diagnostics · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Institute for Neurodegenerative Disorders page
37 registered trials is a research-attention snapshot, not an endorsement of Institute for Neurodegenerative Disorders or any single study.
- None of Institute for Neurodegenerative Disorders's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Parkinson Disease is the condition Institute for Neurodegenerative Disorders studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Parkinson Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Institute for Neurodegenerative Disorders pipeline card: 37 registered trials from official public datasets.Report a data error.